Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM-AD in Patients With Dementia of the Alzheimer's Type

Trial Profile

Open-Label, Single-Center, Phase 1 Clinical Trial to Evaluate the Safety and the Efficacy of NEUROTSTEM-AD in Patients With Dementia of the Alzheimer's Type

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health, NCT01696591: Follow-up) and integrated.
    • 12 Oct 2012 New source identified (ClinicalTrials.gov: US National Institutes of Health, NCT01696591: Follow-up) and integrated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top